Furthermore, Kaplan–Meier survival analysis indicated that low expression of ELAVL2 is associated with dismal outcome in both glioma (p < 0.0001) and only GBM datasets (p = 0.01) (Fig. 2g). Here, ELAVL2 is linked to central nervous system cancer.